EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, PCI Biotech Holding ASA's Enterprise Value is kr-9.04 Mil.
PCI Biotech Holding ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was kr-16.45 Mil. Therefore, PCI Biotech Holding ASA's EV-to-FCF for today is 0.55.
The historical rank and industry rank for PCI Biotech Holding ASA's EV-to-FCF or its related term are showing as below:
OSL:PCIB'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.65
Current: 0.65
During the past 13 years, the highest EV-to-FCF of PCI Biotech Holding ASA was 0.65. The lowest was 0.00. And the median was 0.00.
OSL:PCIB's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 16.26
vs OSL:PCIB: 0.65
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
PCI Biotech Holding ASA's PE Ratio (TTM) for today is calculated as:
PCI Biotech Holding ASA's share price for today is kr0.115.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PCI Biotech Holding ASA's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was kr-0.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSL:PCIB vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, PCI Biotech Holding ASA's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PCI Biotech Holding ASA EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where PCI Biotech Holding ASA's EV-to-FCF falls into.
PCI Biotech Holding ASA's current Enterprise Value is kr-9.04 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. PCI Biotech Holding ASA's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was kr-16.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCI Biotech Holding ASA (OSL:PCIB) has a EV-to-FCF of 0.55 as of Jul. 04, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PCI Biotech Holding ASA and its competitors.
Is PCI Biotech Holding ASA's EV-to-FCF too high?
PCI Biotech Holding ASA's current EV-to-FCF is 0.55. The Biotechnology industry median EV-to-FCF is 16.26. PCI Biotech Holding ASA's value of 0.55 is 96.6% below this industry median. Overall, PCI Biotech Holding ASA has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does PCI Biotech Holding ASA's EV-to-FCF compare to VRTX and REGN?
PCI Biotech Holding ASA's EV-to-FCF of 0.55 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 16.26. PCI Biotech Holding ASA's value of 0.55 is 96.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PCI Biotech Holding ASA's current EV-to-FCF of 0.55 is 96.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on PCI Biotech Holding ASA and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PCI Biotech Holding ASA's current EV-to-FCF is 0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PCI Biotech Holding ASA stock overvalued right now?
PCI Biotech Holding ASA (OSL:PCIB) has a current EV-to-FCF of 0.55. The current EV-to-FCF is 0.55 and 96.6% below the Biotechnology industry median of 16.26. PCI Biotech Holding ASA's overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For PCI Biotech Holding ASA (OSL:PCIB), the current EV-to-FCF is 0.55 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.
6GF Score
Get the complete analysis for OSL:PCIB
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSL:PCIB has been successfully added to your 
